Rivaroxaban

"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Descriptor ID	D000069552
MeSH Number(s)	D02.886.778.727 D03.383.533.640.713 D03.383.903.727
Concept/Terms	Rivaroxaban Rivaroxaban 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide Xarelto Xarelto BAY 59-7939 BAY 59-7939 BAY 59 7939 BAY 597939

Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Sulfur Compounds [D02.886]
Thiophenes [D02.886.778]
Rivaroxaban [D02.886.778.727]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Oxazines [D03.383.533]
Morpholines [D03.383.533.640]
Rivaroxaban [D03.383.533.640.713]
Thiophenes [D03.383.903]
Rivaroxaban [D03.383.903.727]

Below are MeSH descriptors whose meaning is related to "Rivaroxaban".

Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.

Bar chart showing 17 publications over 8 distinct years, with a maximum of 4 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	1	1
2010	0	1	1
2012	0	1	1
2014	0	2	2
2016	3	0	3
2018	2	2	4
2019	2	0	2
2020	3	0	3

Below are the most recent publications written about "Rivaroxaban" by people in Profiles.

Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.

View in: PubMed
Raskob GE, Spyropoulos AC, Spiro TE, Lu W, Yuan Z, Levitan B, Suh E, Barnathan ES. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.

View in: PubMed
Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott GC, Halperin JL, Hiatt WR, Maynard G, Steg PG, Weitz JI, Suh E, Lu W, Barnathan ES, Raskob GE, Spyropoulos AC. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.

View in: PubMed
MacDougall K, Spyropoulos AC. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. Semin Respir Crit Care Med. 2021 04; 42(2):308-315.

View in: PubMed
Lipardi C, Elliott CG, Sugarmann CL, Haskell L, Spyropoulos AC, Raskob GE, Xu J, Lu W, Marsigliano J, Spiro T, Yuan Z, Wu S, Barnathan ES. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.

View in: PubMed
Khan SU, Khan MZ, Asad ZUA, Valavoor S, Khan MU, Khan MS, Krupica T, Alkhouli M, Kaluski E. Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020 Nov; 50(4):913-920.

View in: PubMed
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.

View in: PubMed
Weitz JI, Raskob GE, Spyropoulos AC, Spiro TE, De Sanctis Y, Xu J, Lu W, Suh E, Argenti D, Yang H, Albanese J, Lipardi C, Barnathan ES. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.

View in: PubMed
Boylan PM, Santibañez M. Upper Gastrointestinal Bleeding in a Male Patient Taking Megestrol Acetate and Rivaroxaban: A Case Report. Sr Care Pharm. 2019 Sep 01; 34(8):501-509.

View in: PubMed
Spyropoulos AC, Lipardi C, Xu J, Lu W, Suh E, Yuan Z, Levitan B, Sugarmann C, De Sanctis Y, Spiro TE, Barnathan ES, Raskob GE. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.

View in: PubMed

People

Explore

Similar Concepts

Top Journals